DEFA14A: Amgen Urges Stockholders to Vote in Favor of Board Recommendations at Upcoming Annual Meeting

Amgen encourages stockholders to vote in line with the Board's recommendations at the upcoming Annual Meeting, highlighting the company's strategic execution, commitment to society, and corporate governance practices.

Summary

• Amgen is soliciting stockholder votes for its upcoming Annual Meeting.
• The company highlights its 2023 achievements, including the acquisition of Horizon Therapeutics, advancements in its innovative pipeline, and strong financial performance.
• Amgen's strategy focuses on providing firstor best-in-class medicines for serious diseases, both through internal development and external sourcing.
• The acquisition of Horizon expands Amgen's portfolio into rare inflammatory diseases.
• Amgen's pipeline includes promising treatments in oncology and general medicine, with Breakthrough Therapy Designations granted by the FDA for several cancer treatments.
• The company is also advancing treatments for obesity, including maridebart cafraglutide, currently in Phase 2 clinical trials.
• Amgen invested \$27.8 billion in a strategic business acquisition, \$4.8 billion in research and development, and \$1.1 billion in capital expenditures.
• The company returned \$4.6 billion in dividends to stockholders.
• Amgen is committed to environmental sustainability, aiming for carbon neutrality by 2027 and reductions in water use and waste disposal.
• The company's new facilities in Ohio and North Carolina are expected to support its ability to meet demand and create jobs.
• Amgen's Representation in Clinical Research (RISE) program aims to improve diversity in clinical trials.
• The Amgen Safety Net Foundation and corporate philanthropy assist patients who cannot afford their medicines.
• The Amgen Foundation's science education programs reach approximately 25 million students and teachers worldwide.
• The Board of Directors recommends voting FOR the election of all 12 director nominees, the advisory vote to approve executive compensation, the approval of the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, and the ratification of Ernst & Young LLP as independent registered public accountants.
• The Board emphasizes its commitment to corporate governance best practices, including a highly independent board, stockholder engagement, and compensation practices aligned with performance.
• The Annual Meeting of Stockholders will be held virtually.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment, emphasizing Amgen's strategic achievements, financial performance, and commitment to corporate responsibility. The tone is confident and optimistic about the company's future prospects.

Positives

• Acquisition of Horizon Therapeutics expands Amgen's portfolio and growth potential.
• FDA Breakthrough Therapy Designations highlight the promise of Amgen's oncology pipeline.
• Advancements in obesity treatments address a significant unmet medical need.
• Commitment to environmental sustainability aligns with global goals.
• Return of capital to stockholders through dividends demonstrates financial strength.
• Strong corporate governance practices enhance accountability and transparency.

Future Outlook

Amgen aims to continue delivering innovative medicines, advancing its pipeline, and maintaining a disciplined approach to capital allocation.

Management Comments

• Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President: '2023 was another year of strong execution of our strategy.'
• Robert A. Bradway: 'We acquired Horizon Therapeutics plc (Horizon), advanced our innovative pipeline, and delivered strong performance.'

Industry Context

The acquisition of Horizon Therapeutics reflects a broader trend in the pharmaceutical industry towards consolidation and diversification into specialized therapeutic areas like rare diseases. Amgen's focus on biosimilars and innovative manufacturing aligns with industry efforts to reduce healthcare costs and improve access to medicines.

Comparison to Industry Standards

• Amgen's R&D investment as a percentage of revenue is comparable to other large-cap biotechnology companies like Gilead Sciences and Biogen.
• The company's dividend yield is competitive with other dividend-paying pharmaceutical stocks such as Johnson & Johnson and Pfizer.
• Amgen's environmental sustainability goals are in line with industry peers like Novartis and Roche, which have also set targets for carbon neutrality and emissions reductions.

Stakeholder Impact

• Stockholders are encouraged to vote in favor of the Board's recommendations, which are intended to enhance long-term value.
• Employees benefit from the company's investment in research and development and its commitment to creating a positive work environment.
• Patients benefit from the development of innovative medicines and the Amgen Safety Net Foundation's assistance in accessing needed treatments.
• The company's environmental sustainability efforts contribute to a healthier planet for all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the agenda items outlined in the proxy statement.
• The Annual Meeting of Stockholders will be held virtually on May 31, 2024.

Key Dates

Keywords

Amgen, stockholders, Annual Meeting, Horizon Therapeutics, Board of Directors, corporate governance, executive compensation, equity incentive plan, Ernst & Young, clinical trials, oncology, obesity, sustainability, dividends, FDA, pharmaceuticals, biologics